Impact BioMedical (IBO) has a profit margin of 2254.29%, above the Healthcare sector average of 13.89%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Impact BioMedical's profit margin stands at 2254.29% as of June 2026. That compares with -549628.57% in the prior-year period — up 100.4% year over year. That is above the Healthcare sector average of 13.89%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Impact BioMedical reported 2254.29% in profit margin versus -549628.57% a year earlier — a 100.4% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.
Impact BioMedical sits higher the Healthcare benchmark (13.89%) with a profit margin of 2254.29%. That is roughly 16126.0% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A profit margin of 2254.29% for Impact BioMedical means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Impact BioMedical's profit margin evolved across reporting periods, while the comparison chart places IBO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.